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Abstract
The Nrf2 has been identified as a key molecular player in orchestrating adaptive cel-
lular interactions following a wide spectrum of cellular conditions that could be either 
extracellular or intracellular. The encoded transcription factor regulates genes, which 
contain antioxidant response elements (ARE) in their promoters; many of these genes 
encode proteins involved in response to environmental stress, detoxifying enzymes, 
metabolic enzymes, injury, and inflammation, which includes the production of free 
radicals. The association between oxidative stress and inflammation with progression of 
diabetic nephropathy and cardiomyopathy has been described. The prevention of dia-
betic nephropathy and cardiomyopathy has become a global concern for those who are 
working in diabetic care management. Therefore, activation of Nrf2 has the potential to 
protect against macromolecular damage. Studies have demonstrated the beneficial role 
of Nrf2 induction in the prevention of DN. Upon exposure of cells to oxidative stress or 
electrophilic compounds, Nrf2 dissociates from Keap1 and translocates into the nucleus 
to bind to antioxidant-responsive elements in the genes encoding antioxidant enzymes. 
Upregulation of these Nrf2-dependent antioxidants promotes detoxification and anti-
inflammatory function. Thus, the Nrf2 activators have been suggested for preventing 
diabetic nephropathy.
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1. Introduction
The stimatives demonstraded that 10% of the global population will have diabetes by 2035 [1]. 
Hyperglycemia, hyperlipidemia, and inflammation are the metabolic abnormalities in diabetes 
and are involved with the development of reactive oxygen or nitrogen species (ROS or RNS) [2].
© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
Diabetes is a strikingly heterogeneous disease with variable clinical, pathologic, and molecu-
lar features [1]. It has been described that high glucose induces the oxidative damage and it is 
related potentially on the diabetic complications in animal models [3].
Additionally, it is known that Nrf2 expression increases in response to oxidative stress [2]. 
The Nrf2 transcription factor (nuclear factor, erythroid 2derived 2-like 2 or nuclear factor 
erythroid 2-related factor 2) has been identified as a key molecular player in orchestrating 
adaptive cellular interactions following a wide spectrum of cellular conditions that could be 
either extracellular or intracellular [3].
Upregulation of Nrf2 and/or its downstream antioxidant genes in response to hyperglycemia 
is of growing interest in the clinical and research community [2]. The Nrf2 is a master regulator 
of cellular detoxification response and redox status and also provides a protective action from 
various oxidative stresses and damages [1, 2]. Given that we have yet to understand molecular 
mechanisms of diabetes complications, the results of studies may play an important role in 
elucidating the molecular pathways and get the development of strategies for prevention, treat-
ment, and management of macrovascular and microvascular diseases (diabetes complications).
2. Implications of Nrf2 transcription factor in diabetic complications
The gene Nrf2 also known as NFE2L2 encodes a transcription factor that regulates genes that 
contain antioxidant response elements (ARE) in their promoters; these genes encode pro-
teins involved in response to environmental stress, detoxifying enzymes, metabolic enzymes, 
injury, and inflammation, which includes the production of free radicals. During nonstressed 
conditions, the Nrf2 is inactive in the cytoplasm connected to protein Kelch-like ECH-
associated protein 1 (Keap1), which prevents its translocation to the nucleus [4].
During oxidative stress, a signal that involves phosphorylation and/or redox modification is 
transduced to the Keap1/Nrf2 complex (see Figure 1), leading to its disruption and nuclear 
translocation of Nrf2. However, under basal conditions, Keap1 mediates rapid ubiquitination 
and subsequent degradation of Nrf2 by the 26S proteasome [3, 4]. Cullin 3-based ubiquitin E3 
(Cul-E3) ligase complex ubiquitinates Nrf2, and Keap1 serves as a substrate adaptor, which 
facilitates the ubiquitination of Nrf2 by Cullin 3. As a result, Nrf2 has a short half-life that 
lasts only 20 min under normal conditions. Oxidative stress destroys critical cysteine residues 
in Keap1, disrupting the Keap1-Cul3 ubiquitination system. If Nrf2 is not ubiquitinated, it 
builds up in the cytoplasm and is translocated into the nucleus [4–6].
In the nucleus, Nrf2 combines with a small protein called Maf to form a heterodimer, and, 
by binding to the ARE in the upstream promoter region, it initiates the transcription of 
various cytoprotective genes including those encoding antioxidant and phase II detoxify-
ing enzymes such as catalase (CAT), superoxide dismutases (SODs), heme oxygenase-1 
(HO-1), NAD(P)H dehydrogenase (quinone) 1 (NQO-1), glutathione peroxidase-1 (GPx-1), 
glutathione S-transferase (GST), and γ-glutamylcysteine synthase (γ-GCS). The antioxidant 
response provided by the NFE2L2 and Keap1-NFE2L2/ARE signaling pathways protects the 
pulmonary, hepatic, digestive, neural and cardiovascular systems, and Nrf2 is considered a 
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promising target against diabetic complications such as cardiovascular diseases and diabetic 
nephropathy [7–9].
Type 2 diabetes mellitus (T2DM) is characterized by insulin resistance, with or without 
defects in insulin production and secretion, and as the prevalence of obesity in children has 
increased, T2DM has also become more common. T2DM is characterized by insulin resistance 
(with or without defects in insulin production and secretion), and the routine medical treat-
ment is challenging, especially the identification and management of complications associ-
ated with micro- and macrovascular damage in diabetes [10].
Diabetes is a multifactorial process involving genetics, lifestyle, ethnic and racial heritage, 
and environmental factors. On the other hand, the interplay of these factors is not yet under-
stood. The single nucleotide polymorphisms (SNPs) are a common type of genetic variations, 
which have been shown to impact most population susceptibility to diseases and individual 
response to drug treatments [10, 11].
In Chinese population was investigated NFE2L2 SNPs for possible associations with either 
T2DM or diabetic complications such as diabetic foot, microangiopathy and peripheral neu-
ropathy, nephropathy, and retinopathy. This study showed that the T2DM patients with 
complications presented a higher frequency of mutant allele than the T2DM patients without 
complications. The study suggests that NFE2L2 SNPs are associated with T2DM patients 
with complications [10].
Figure 1. Schematic presentation of Nrf2 pathway activation by reactive oxygen species (ROS). Under basal conditions, 
Keap1 mediates rapid ubiquitination and subsequent degradation of Nrf2 by the 26S proteasome. During oxidative 
stress, the Nrf2 regulates genes, which contain antioxidant response elements (ARE) in their promoters.
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With oxidative stress and chronic systemic inflammation inseparably interconnected, inhib-
iting oxidative stress was theoretically an effective strategy to delay diabetes-related mac-
rovascular and renal diseases. Research has revealed that the expressions of Nrf2-mediated 
anti-oxidative enzymes, including HO-1, NQO-1, and GPx-1, were significantly increased in 
the diabetic kidney when treated with salvianolic acid A (SAA) alone or in combination with 
metformin (MET). SAA is a polyphenol derivative extracted from the root of Salvia miltior-
rhiza, which is known to show a variety of pharmacological activities including antioxidant, 
anti-inflammatory, and antiplatelet properties [8, 9].




-mediated oxidative stress via activation of Nrf2/HO-1 sig-
naling. The MET is an oral hypoglycemic agent, which is widely used in patients with type 
2 diabetes. MET decreases blood glucose levels by decreasing hepatic glucose production, 
decreasing intestinal absorption of glucose, and improving insulin sensitivity by increasing 
peripheral glucose uptake and utilization [8–10].
Compared to treatment with either SAA or MET alone, their combination provided fur-
ther protection against the macrovascular and renal injury, which was at least partly due 
to therapeutic activation of both MET-mediated AMP-activated protein kinase (AMPK) 
and SAA-mediated Nrf2/antioxidant response elements (ARE) pathways [12]. It is sug-
gested that polyphenol Nrf2 modulators, especially combined with drugs activating AMPK 
including hypoglycemic drugs, are worthy of further investigation to combat diabetic com-
plications [9].
The genetic deficiency in Nrf2-mediated transcriptional responses, especially antioxidant 
pathways, enhances susceptibility to both ischemic and nephrotoxic AKI in mice. Nrf2 defi-
ciency is associated with an increased mortality accompanied by augmented kidney dysfunc-
tion and vascular permeability. Liu et al. [13] demonstrated that Nrf2 deficiency enhances 
susceptibility to both ischemic and nephrotoxic acute kidney injury and identifies this tran-
scription factor as a potential therapeutic target in these injuries.
On the other hand, Nrf2 plays a protective role in experimental acute kidney injury, and this 
protection is mediated, in part, through an endogenous antioxidant pathway [2, 13].
Diabetic cardiomyopathy (DCM) is one of the major cardiac complications in diabetic patients. 
DCM is related to oxidative stress that is due to imbalance between ROS and/or reactive nitro-
gen species generation and their clearance by antioxidant defense systems [2–6]. Experimental 
and clinical studies have shown the important roles that Nrf2 and its downstream genes play 
in the pathogenesis of cardiac remodeling and heart failure induced by a number of factors. 
TNF-α has an important role in a number of pathologies associated with oxidative stress 
including diabetes, cancer, cardiac hypertrophy, and cardiomyopathy [6, 13].
The exposure of TNF-α to cells at concentrations well below the threshold associated with 
subinflammation significantly increased Nrf2 activity and its nuclear translocation. The 
TNFR1/2 double knockout mice and HL-1 cardiomyocytes make a first step forward in under-
standing the bimodal effects of the cytokine, TNF-α, in regulating the redox-sensitive Keap1/
Nrf2 antioxidant pathway. This study has potential importance in the field of cardiovascular 
signaling because the TNF-α–induced biphasic regulation of the Nrf2 pathway suggests that 
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a certain threshold of TNF/ROS signaling is essential to prime and activate the Nrf2 protective 
signaling pathway [14].
Research revealed that broccoli sprout extract (BSE), a natural SFN-rich supplement, can 
prevent the development of DCM. Like sulforaphane (SFN, an Nrf2 activator), BSE can pre-
vent DCM in a transgenic T2DM mouse model via activation of Nrf2 by inhibiting diabetes-
induced cardiac oxidative stress and damage as well as inflammation. BSE, when used at 
higher doses, can be used as a natural and safe source of SFN to upregulate Nrf2 expression 
and prevent DCM. Similar to its reported beneficial impact when used in patients with other 
chronic diseases, our results demonstrate that BSE also has promising potential in the treat-
ment of patients with diabetes mellitus. Treatment with SFN-rich BSE for 3 months could 
significantly prevent the pathological process of DCM in the T2DM mice model, and like SFN, 
BSE also significantly upregulated Nrf2 expression and function to prevent diabetes-induced 
cardiac oxidative stress and inflammation. Therefore, BSE could potentially be used as a natu-
ral and safe treatment against DCM via Nrf2 activation [11].
Coronary artery disease and ischemic heart disease are prevalent worldwide. The devel-
opment of percutaneous coronary intervention and surgical revascularization has brought 
marked benefits to patients with acute MI. However, ischemia/reperfusion injury during 
revascularization can cause further cardiac injury. Nrf2 and its target genes have been shown 
to play a protective role in cardiac ischemia-associated injury. Some antioxidants protect 
the heart from ischemia-induced cardiac injury via the Nrf2 pathway. For example, α-lipoic 
acid and prostaglandin D2 significantly increased Nrf2 nuclear translocation; the expression 
of its downstream genes reduced lactate dehydrogenase (LDH) and creatine kinase (CK) 
release, attenuated myocardial infarct size, decreased cardiomyocyte apoptosis, and partially 
preserved heart function; and this effect was at least partially PI3K/Akt signaling pathway 
dependent [6, 14, 15].
In adipose tissues, ROS promote the conversion from preadipocytes to mature adipocytes 
and facilitate insulin action [16, 17]. The ROS-mediated biological signaling pathways could 
be affected by enhanced Nrf2-ARE activity because ROS signaling intermediates should 
inversely correlate with the ROS scavenging activity and antioxidant status in cells. Thus, 
when the cells are chronically exposed to oxidative stressors, cellular ROS scavenging capac-
ity is adaptively upregulated, primarily through the activation of Nrf2 and subsequent tran-
scriptional induction of a suite of antioxidant enzymes [11].
Additionally, the induced antioxidant enzymes may have the undesired effect of impeding the 
physiological role of ROS as signaling molecules. Although antioxidants protect adipocytes 
from oxidative damage, they also may blunt aspects of ROS signaling, resulting in reduced 
adipogenesis and insulin resistance. Nrf2 controls white adipose tissue expandability and 
serves to maintain glucose and lipid homeostasis, including control of adipogenesis [19–21]. 
In addition, ROS, whose cellular concentrations decline with increases in Nrf2-regualted anti-
oxidant gene expression, also affect insulin signaling [17, 18].
It is described that oxidative stress is a dynamic condition characterized by an imbalance 
between pro-oxidants and antioxidants. Reactive oxygen species (ROS), not adequately 
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 counterbalanced by antioxidant defenses, causes DNA damage. However, it is the action of 
antioxidants such as the Nrf2 transcription factor that acts by activating cytoprotective genes, 
which promote cell survival. In basal conditions, the repressor protein Keap1 binds Nrf2 in 
the cytoplasm and promotes its degradation. In the presence of ROS, Keap1 is inactivated and 
releases Nrf2 resulting in its nuclear translocation. The presence of mutations of the Nrf2-
Keap1 genes and favoring greater Nrf2 expression and action have been described in associa-
tion with different types of diseases. Recently, we have demonstrated the critical role of Nrf2 
expression in protecting the cardiac cells from oxidative damage and death caused by high 
levels of glucose [19, 20, 22]. Thus, the cells have evolved endogenous defense mechanisms 
against sustained oxidative stress.
Experimental studies have shown that oxidative stress directly induces insulin resistance 
in cardiomyocytes via exaggerating extracellular signal-related kinase (ERK) activity in 
vitro. Additionally, depressed expression of cardiac Nrf2 was associated with significant 
increases in nitrosative damage and phosphorylation of ERK, all of which were prevented 
in the hearts of diabetic mice with cardiac overexpression of a potent antioxidant metallo-
thionein (MT) [23, 24].
On the other hand, upregulation of cardiac Nrf2 by its activator dihydro-CDDO-trifluoro-
ethyl amide (Dh404) significantly prevented diabetes-induced nitrosative damage, ERK acti-
vation, and insulin signaling downregulation. Thus, these findings suggest that oxidative 
stress–depressed expression of cardiac Nrf2 is associated with cardiac activation ERK 
and downregulation of glucose metabolism [25]. The studies suggested that the Nrf2 is 
a master transcriptional factor of antioxidative defense system [19] and may be a novel 
negative regulator of oxidative stress–mediated insulin resistance in cardiomyocytes and 
the heart [22].
Traditionally, interactions among metabolic and hemodynamic factors are considered to be 
involved in the development of renal lesions in patients with diabetes, for example, diabetic 
nephropathy (DN). However, several other factors such as oxidative stress and inflammatory 
processes have been shown to play important roles in the pathogenesis of DN; these factors 
are not completely independent, but they interact with each other. Several studies report the 
infiltration of macrophages and proinflammatory cells in kidney at different stages of DN 
[26]. The inflammatory infiltrate produces reactive oxygen species (ROS), proinflammatory 
cytokines, and growth factors, which lead to upregulation of chronic systemic inflammation 
and mediate the progression of diabetic nephropathy [26, 28–30].
As a consequence of inflammation, a variety of cytokines and acute phase proteins are released 
in order to augment or attenuate the inflammatory response. The main inflammatory cytokines 
involved in the development of DN are interleukin 1 (IL-1), IL-6, and IL-18 and tumor necrosis 
factor-α (TNF-α); these might contribute to the progression of renal injury either directly or 
indirectly [27]. Thus, chronic inflammation contributes to DN not only as a consequence of a 
direct effect of proinflammatory mediators on cellular signaling but also by creating a state 
of oxidative stress. In recent years, several investigators have provided substantial evidence 
implicating nuclear factor Nrf2 in inflammation and associated disorders [30, 31].
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The therapeutic potential of Nrf2 activation in diabetes, implicating control of oxidative 
stress, in addition to regulation of inflammatory cytokines as methods of Nrf2 protection, was 
described. Also, it has been described that severe oxidative stress is associated with inflamma-
tion in chronic kidney disease (CKD) [27]. Oxidative stress and inflammation are mediators 
in the development and progression of chronic kidney disease (CKD) and its complications, 
and they are inseparably linked as each begets and amplifies the other. Although pathways 
involved in intrarenal ROS production and inflammation in experimental CKD have been 
widely explored, the relationship of DN on proinflammatory cytokines and Nrf2-Keap1 sys-
tem in diabetes is poorly studied [27, 28, 30].
There was no an effective approach to prevent the development of these complications for the 
patients with diabetes. Thus, diabetic nephropathy and cardiomyopathy are the two major 
causes for the mortality of diabetic patients. Although there remain many questions to be 
further investigated, the potential beneficial effects of upregulation of Nrf2 and/or its down-
stream protective components have attracted the attention of basic researchers and clinical 
physicians to consider its potential application in the clinic [5–30].
3. Strategies to prevent diabetic complications by activating Nrf2 factor
The glucose control, blood pressure, lipid lowering, and the blockage of the renin-angiotensin 
systems were used for the treatment of diabetic patients, and the development and progres-
sion of nephropathy and cardiomyopathy in the patients with diabetes remain unpreventable 
[2]. Ultimately, it can be inferred that these Nrf2 cross talks with other signaling pathways 
are of clinical importance within the context of many human disease condition pathogenesis, 
particularly those with highly complex multifactorial molecular interaction, as in diabetic 
complications [32].
Diabetic nephropathy (DN), one of the major microangiopathic chronic diabetic complica-
tions, is associated with an increased risk of major cardiovascular events and all-cause mor-
tality. DN is now the major cause of chronic kidney disease throughout the world and is the 
largest single cause of end-stage renal disease, accounting for nearly half of the patients enter-
ing dialysis each year. The etiopathogenesis of DN is clearly multifactorial, including genetic 
and environmental factors. Evidence indicates that mechanisms are active by mitochondrial 
overproduction of reactive oxygen species (ROS) [34, 37].
Extra generation of ROS, induced by hyperglycemia, is considered as the main reason for the 
development of these diabetic complications. Oxidative stress contributes to the pathogenesis 
of diabetic nephropathy. Nuclear factor erythroid-derived 2-like 2 (NRF2) controls cellular 
defense mechanisms against oxidative stress by turning on transcription of antioxidant genes 
[33]. Under physiological conditions Kelch-like ECH-associated protein 1 (Keap1) binds to 
Nrf2 and sequesters it in the cytoplasm. Under basal conditions, Keap1 mediates rapid ubiq-
uitination and subsequent degradation of Nrf2 by the proteasome [7, 35, 36, 38]. Studies have 
demonstrated the beneficial role of Nrf2 induction in the prevention of DN [37].
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Upon exposure of cells to oxidative stress or electrophilic compounds, Nrf2 dissociates from 
Keap1 and translocates into the nucleus to bind to antioxidant-responsive elements in the 
genes encoding antioxidant enzymes. Upregulation of these Nrf2-dependent antioxidants 
promotes detoxification and anti-inflammatory function. A growing body of evidence has 
indicated a critical role for activator-induced Nrf2 upregulation in the prevention of diabetic 
complications, including DN [36].
Other important targets of the Nrf2/Keap1/ARE system are lipogenic genes involved in regula-
tion of triglyceride and cholesterol synthesis and metabolism, such as sterol response element-
binding protein-1 and fatty acid synthase, where activation of Nrf2 leads to downregulation 
of lipogenic gene expression, affording protection against lipogenic stress. Repression of ste-
rol response element-binding protein-1 decreased expression and activities of diacylglycerol 
acyltransferase-1 and 2 activity and fatty acid synthase, leading to decreased synthesis of 
triglycerides and cholesterol esters and secretion of apolipoprotein B100 in very low-density 
lipoprotein. Therefore, activation of Nrf2 has the potential to protect against macromolecular 
damage and against metabolic dysfunction and dyslipidemia [37].
Given these considerations, the preventive effect of Nrf2 activation on diabetic complication in 
animal models has been explored recently. The Nrf2 activators have been suggested for pre-
venting diabetic nephropathy such as insulin, sulforaphane (SFN), cinnamic aldehyde (CA), 
and others. It is know that NQO1, one important Nrf2 downstream protective components, 
which is an important detoxifying enzyme that protective against  diabetic complications. 
Functional variants of NQO1 were associated with the development of coronary artery disease 
in people with type 2 diabetes [35].
Studies have shown that after chronic treatment with SFN, that diabetic mice exhibited signifi-
cant renal prevention from diabetes-induced damage most likely via induction of Nrf2-mediated 
antioxidant pathway. SFN has garnered particular interest as an indirect antioxidant due to its 
extraordinary ability to induce expression of several enzymes via the Keap1/Nrf2 pathway. The 
studies indicate the requirement of Nfr2 for SFN and CA-induced renal protection against dia-
betes [37]. The activation of Nrf2 by SFN is able to suppress hyperglycemia-induced oxidative 
stress and metabolic dysfunction in human microvascular endothelial cell [37].
Anti-inflammatory, antioxidant, and antimicrobial effects of curcumin products have been 
widely investigated recently [9–41]. The analog C66 from curcumin was found to effectively 
inhibit high glucose (HG)-induced inflammatory response and macrophage infiltration, 
resulting in a significant prevention of renal injury in diabetic rats, response, and macrophage 
infiltration, resulting in a significant prevention of renal injury in diabetic rats. Liu et al. [39] 
demonstrated for the first time that C66 can protect the aorta from diabetes using a type 1 dia-
betes mouse model. Treatment of diabetic mice with C66 for 3 months can almost completely 
reverse and/or prevent the progression of diabetes-induced aortic oxidative damage, inflam-
mation, apoptosis, and proliferation.
C66 is a novel curcumin analog with a much lower effective dose of 5 mg/kg administered 
every other day and has been shown to establish protection from diabetic nephropathy and 
diabetic cardiomyopathy [7, 40]. Wu et al. [8] have demonstrated that in addition to upreg-
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ulating Nrf2 by increasing miR-200a, C66 also protects against DN by inhibiting miR-21. 
Curcumin is a regulator of epigenetic events, including miRNAs, and among miR-21 has 
been demonstrated to play a key role in the pathogenesis of DN. Liu et al. described that 
C66’s renal protection from diabetes was accompanied by a significant inhibition of c-Jun 
N-terminal kinase (JNK). Inhibition of JNK phosphorylation by C66 and JNKi also signifi-
cantly prevented diabetes-induced increase in inflammation, oxidative and nitrative stress, 
apoptosis, cell proliferation, and fibrosis [39].
The health-beneficial effects of fruit and vegetables have been linked to their content of activa-
tors of Nrf2. Key dietary bioactive activators of this system are glucosinolate-derived dietary 
isothiocyanates (SFN) and indoles, thioethers and disulfides, polyphenols, flavonoids, carot-
enoids, oxidized omega-3 fatty acids, and triterpenoids. Additionally, SFN is found in the 
brassica vegetables (broccoli, cabbage, cauliflower, Brussel sprouts, and others) and rocket 
salad [11]. The diet as a source of anti-inflammatory and health-beneficial compounds for 
patients with chronic renal failure has been recognized. With markedly decreased clearance 
in this patient group and adverse effects of some dietary bioactive compounds at high doses, 
particularly glucosinolate-derived isothiocyanates, it is necessary to proceed cautiously with 
dietary recommendations [38].
The activation is thought to occur by different mechanisms: SFN releases Nrf2 from Keap1 by 
modification of critical cysteine thiol residues; some polyphenols induce downregulation of 
Keap1 expression and/or induce mild oxidative/nitrosative stress; and J3-isoprostanes disrupt 
the Keap1-Cul3 complex, preventing Keap1-Nrf2 targeting to the proteasome. Many chemi-
cally diverse activators have already been identified, including the glutathione peroxidase-1, 
SN found in cruciferous vegetables, caffeic acid phenethyl ester from the bee product propolis, 
and CA (found in cinnamon bark) [37]. Many have shown promising actions relevant to dia-
betes complications [38]. Dietary habits may also be difficult to change, but processing of food 
products and beverages may also be modified to increase levels of Nrf2 activators in foodstuffs. 
It is generally accepted that a diet rich in fruits and vegetables helps stave off the development 
of cardiovascular disease [38].
Dietary and synthetic activators use as secondary prevention measure for DN should remain 
a top priority for health official campaigns [41]. To reach the public health goal of reduc-
ing DN prevalence, campaigns to engaging in diabetic complications prevention need to be 
addressed, including dietary education strategies.
4. Conclusions
Oxidative stress is a major player in the etiology of diabetic complications. Given these 
considerations, the Nrf2 factor is a master regulator of redox homeostasis and the cellu-
lar detoxification response. It has been demonstrated that natural compounds derived from 
plants, vegetables, and micronutrients can activate Nrf2 and, thus, promote antioxidant 
pathways to mitigate oxidative stress and hyperglycemic damage. Studies are needed to 
evaluate the potential effect of Nrf2 activators. Thus, these activators play an important role 
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in stress oxidative, such as a therapeutic strategy in preventing the development of diabetic 
complications.
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